Vendor Intelligence Report: Injectify

Published 3 Jul 2026. 25-page investigative report on who is behind Injectify: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Injectify is a mixed vendor, not a one-word verdict. Across 30 Finnrick lab tests, the record is 16 pass / 14 fail, an overall pass rate of 53%. The dispersion matters more than the average: Semaglutide and Melanotan II are the better-tested choices, while CJC-1295 and BPC-157 define the weak side of the catalog, with identity and label-variant problems in the underlying file. Ratings also move under stricter grading, reinforcing a product-by-product read.

The operating record is unusually time-sensitive. Injectify's own policies identify INJ BIO LABS LLC as the operator and state New York LLC status, but the registry trail could not confirm formation details, registered agent, members, or managers. Storefront evidence shows the advertised closure moved from July 1 to August 1, 2026 while U.S. and Canadian shops kept taking final-sale orders.

Beyond assay results, the report tracks the practical risks of buying from a liquidating cross-border peptide storefront: limited post-sale recourse, crypto-payment indicators, brand-confusion conditions around the old injectify.ca migration, and an affiliate-code ecosystem that remains active despite the shutdown messaging. The report also separates GLP-class enforcement exposure from analytical quality, so a better-tested Semaglutide vial is not confused with a lower-risk transaction.

Inside the full report:

  • Per-product pass/fail rates, sparkline trajectories, and methodology-divergence charts for all six tested products
  • Storefront captures documenting the July-to-August closure-date change, U.S./Canada final-sale pages, and INJECTIFY15 language
  • Terms of Service and Shipping Policy captures naming INJ BIO LABS LLC and documenting cross-border operations
  • Infrastructure trail for injectify.is, us.injectify.is, ca.injectify.is, affiliate, invoicing, and staging subdomains
  • Affiliate and promotion map covering Facebook, Reddit, coupon aggregators, SpendMoneySmart X amplification, and disclosure assessment
  • Regulatory and peer-market context including Health Canada/CPSA warnings and the Strate Labs closure notice

Risk assessment

  • Product mislabeling risk (CJC-1295) — high: CJC-1295 no-DAC / Ipamorelin blend: Finnrick shows 0 pass / 7 fail and 15.96%; field analysis identified DAC-variant mismatch in no-DAC-labeled material.
  • Product identity and quality failure risk (BPC-157) — high: BPC-157 shows 2 pass / 5 fail and 42.24%; field analysis recorded samples containing no BPC-157.
  • Regulatory-enforcement and availability risk (GLP-class products) — high: Semaglutide, retatrutide and tirzepatide sit in a US/Canada enforcement-sensitive category; peer Strate Labs closed after GLP-related pressure, and Injectify is liquidating.
  • Post-closure support and fulfillment risk — medium: All products: storefronts announce an August 1, 2026 closure and final sale, reducing confidence in returns, replacements and batch follow-up after purchase.
  • Batch-consistency risk (Ipamorelin and Retatrutide) — medium: Ipamorelin and Retatrutide each show 3 pass / 1 fail, with ratings of 70.46% and 78.69%; better than the failure-heavy products but still batch-dependent.
  • Payment-recourse risk — medium: All products: checkout/source review recorded cryptocurrency payment plugins and no ordinary card chargeback path in the captured checkout environment.
  • Affiliate-promotion and disclosure risk — medium: Formal affiliate infrastructure and visible code promotion; several scanned code/link promoters lacked clear disclosure.
  • Brand-confusion and unofficial-channel risk — medium: Old injectify.ca migration, US/CA subdomains, social-handle ambiguity and coupon/deal pages; no captured authorized-channel list or batch-verification system.